Read More

ADC Therapeutics And Sobi Announce European Commission Approval Of ZYNLONTA For The Treatment Of Relapsed Or Refractory Diffuse Large B-Cell Lymphoma; Approval Triggers $50M Milestone Payment To ADC Therapeutics

Approval triggers $50 million milestone payment to ADC Therapeutics ADC Therapeutics SA (NYSE:ADCT) and Swedish Orphan Biovitrum AB (Sobi®) today announced the European Commission (EC) has granted

ADCT